Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01919723 · ClinicalTrials.gov registry record · Phase 2
Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT01919723 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 70 participants.
The verdict
NCT01919723, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This purpose of this study is to measure platelet response to ticagrelor and eptifibatide bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion administrated after cardiac catheterization in patients undergoing non-emergent percutaneous coronary intervention.
Interventions
- DRUG Ticagrelor
- DRUG Eptifibatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01919723
The ClinicalTrials.gov registry entry for NCT01919723 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ticagrelor is the first listed.
NCT01919723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01919723 about?
NCT01919723 is a clinical study titled "Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion". This purpose of this study is to measure platelet response to ticagrelor and eptifibatide bolus-only compared with ticagrelor and eptifibatide bolus plus 2-hour infusion administrated after cardiac catheterization in patients undergoing non-emergent percutaneous coronary intervention.
What is the current status of trial NCT01919723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01919723?
The interventions under investigation include: Ticagrelor (DRUG), Eptifibatide (DRUG).
Who is sponsoring clinical trial NCT01919723?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.